Microba Life Sciences (MAP) Q2 2025 earnings summary

Executive summary

• Q2 FY25 revenue reached $4.43 million, up 102% year-over-year, with cash receipts of $3.87 million, up 109% year-over-year.

• Half-year revenue totaled $8.08 million, a 147% increase year-over-year, reflecting strong sales momentum.

• MetaXplore test sales in Australia rose 195% year-over-year, with over 2,560 tests sold and a 105% increase in ordering clinicians.

• UK MetaXplore early access program delivered clinician referral rates consistent with Australia, supporting accelerated market access in H2 FY25.

• Therapeutics pipeline advanced, with MAP315 for IBD moving to Phase 2 and expanded immuno-oncology and autoimmune programs.

Financial highlights

• Q2 FY25 revenue: $4.43 million (+102% YoY); H1 FY25 revenue: $8.08 million (+147% YoY); cash receipts: $3.87 million (+109% YoY).

• Cash balance at 31 December 2024: $17.3 million.

• Personal Testing & Supplements revenue was $3.5 million, up 132% year-over-year; Research Testing revenue was $0.92 million, up 35%.

• Supplements sold in Q2 FY25 totaled 32,833, up 8% year-over-year.

• Net cash from operating activities in Q2 FY25 was $1.8 million.

Outlook and guidance

• MetaXplore adoption expected to accelerate in Australia and UK, with full UK market access targeted for H2 FY25.

• Therapeutics programs advancing, with MAP315 Phase 2 IND submission in progress and ongoing strategic partnering.

• Focus on diagnostics and therapeutics growth, with continued investment in international expansion.